MiNDERA Corp.
Non-invasive molecular testing for skin cancer
This article was originally published in Start Up
Executive Summary
MiNDERA Corp. is developing an alternative to punch biopsies for diagnosing skin cancer: its microneedle device extracts biomarkers from the skin in a procedure that the start-up says is highly accurate and cost-effective for office-based diagnostic applications in dermatology.